Table 3. Characteristics of study sample for whole exome sequencing.
| Patient demographics | Responders | Non-responders |
|---|---|---|
| Self-reported gender, % female | 77.5 | 80.2 |
| Age, mean (S.D) years | 54.5+/-15 | 54.7+/-12 |
| Duration, years | ||
| Mean (S.D.) | 8.9+/-10.4 | 7.5+/-7.8 |
| Median (interquartile range) | 4.7 (1.5–13.3) | 4.0 (1.7–11.0) |
| Disease duration <2 years, n (%) | 13 (32.5) | 21 (25.9) |
| Tender joint count, mean (S.D.) | 14.4+/-7.0 | 15.7+/-7.0 |
| DAS 28 (ESR), mean (S.D.) | 6.3+/-1.0 | 6.3+/-1.1 |
| ACR20 at week 6, n (%) | 34 (85.0) | 0 (0.0) |
| ACR20 at week 12, n (%) | 40 (100) | 0 (0.0) |
| ACR70 at week 6, n (%) | 12 (30.0) | 0 (0.0) |
| ACR70 at week 12, n (%) | 40 (100) | 0 (0.0) |
| Self-reported ethnicity, n (%) | ||
| Caucasian | 30 (75) | 75 (93) |
| CRP, mg/l; Median (interquartile range) | 9 (3.8–21.3) | 7 (4.0–16.0) |
| ESR, mm/h: Median (interquartile range) | 42.0 (26.3–57.8) | 38.0 (27.0–52.0) |
| Anti-CCP positive at baseline, n (%)a | 24 (66.6) | 45 (61.6) |
| RF positive at baseline, n (%)a | 28 (75.7) | 57 (76.0) |
| Treatment history | ||
| Previous TNF inhibitor use, n (%)a | 16 (40.0) | 37 (45.6) |
| Other Medication at baseline, n (%) | ||
| Methotrexate | 32 (80.0) | 59 (72.8) |
| Steroids | 26 (65.0) | 47 (58.0) |
| Statins | 7 (17.5) | 20 (24.7) |
| Lefluonamide | 0 (0.0) | 3 (3.7) |
| Azathioprine | 0 (0.0) | 0 (0.0) |
aIncomplete clinical data.